Onco Wiki - Régimen

Ciltacabtagene autoleucel (cilta-cel) BCMA CAR-T for lenalidomide-refractory R/R multiple myeloma after 1-3 prior lines — single infusion after Flu/Cy lymphodepletion (CARTITUDE-4)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.

Fuente YAML: registro completo

ComponentesNinguna declarada
IDREG-CILTACEL-MM-2L
TipoEsquema terapéutico
Situaciónreviewed 2026-04-29 | pending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-CARTITUDE-1-BERDEJA-2021 SRC-NCCN-MM-2025

Notas

CARTITUDE-4 (NCT04181827, San-Miguel NEJM 2023, PMID 37272512): randomized phase-3 of single-infusion cilta-cel vs investigator's choice (PVd or DPd) in lenalidomide-refractory R/R multiple myeloma after 1-3 prior lines (n=419, 1:1 randomization). Cilta-cel arm: ORR 84.6%, sCR 73.1%; mPFS not reached vs 11.8 mo control (HR 0.26, p<0.001); 12-mo PFS 75.9% vs 48.6%. Established cilta-cel as superior to standard-of-care triplets in lenalidomide-refractory 2L+ MM. FDA approval Apr 2024 (this 2L indication). MNT mitigation strategies (low tumor burden via bridging, prompt CRS/ICANS rx) reduced delayed-onset neurotoxicity from ~5% (CARTITUDE-1) to ~1% (CARTITUDE-4). Centre must be FACT/JACIE/REMS-accredited. Boxed warnings unchanged from CARTITUDE-1 (CRS, ICANS, MNT, HLH/MAS, prolonged cytopenia, secondary T-cell malignancy). Single curative-intent attempt; no maintenance. STUB — pending Co-Lead sign-off. Bibliographic record SRC-CARTITUDE-4-SAN-MIGUEL-2023 (NEJM PMID 37272512) is available; source-to-claim mapping, including trial-design and safety context, requires dual clinical review.

Utilizado por

Indicación

Esquema terapéutico